<DOC>
	<DOCNO>NCT03082287</DOCNO>
	<brief_summary>The ALPCO Calprotectin ELISA vitro diagnostic test intend quantitatively measure concentration fecal calprotectin human stool sample . Calprotectin protein biomarker mucosal inflammation . Measurement calprotectin aid diagnosis Inflammatory Bowel Diseases ( IBD ) , specifically Crohn 's Disease ( CD ) Ulcerative Colitis ( UC ) , well aid differentiation IBD Irritable Bowel Syndrome ( IBS ) use conjunction diagnostic test total clinical picture . This study estimate predictive value negative ( NPV ) positive ( PPV ) test utilize assay outcome ALPCO Calprotectin ELISA .</brief_summary>
	<brief_title>ALPCO Calprotectin ELISA - Measurement Calprotectin Levels Human Stool</brief_title>
	<detailed_description />
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<criteria>Inclusion Criteria ( IBD IBS subject ) : &gt; 18 year age Patient must present sign symptom IBS IBD Patient must schedule colonoscopy All result colonoscopy include histology must provide study site sponsor . Medical Chart review may require confirm diagnosis IBS IBD Patient must take NSAIDs least 2 week prior participate study . Patients may advise study report take NSAIDS may enrol study patient stop use NSAIDS minimum 2 week . For normal patient population study participant must present sign symptom IBS IBD , must take NSAIDs least period 2 week must willing provide stool sample . Sample must collect least 23 day prior colonoscopy Inclusion Criteria ( normal subject ) : Male female , â‰¥18 year age . No abdominal complaint history IBS , IBD , chronic intestinal disorder , confirm medical history physical examination enrollment . May undergone colonoscopy negative finding within past 1 month may recent colonoscopy , schedule routine screening colonoscopy . Able understand study task require , sign ICF . Exclusion Criteria ( IBD IBS Subjects ) : patient age 18 Patient take NSAIDs Patients present sign symptom IBS IBD exception 100 normal patient include study . Fifty ( 50 ) present routine colonoscopy 50 patient present disease symptom schedule colonoscopy . Patients schedule colonoscopy unless enrol study normal population Exclusion Criteria ( normal subject ) : Unable unwilling provide stool specimen . Have take protein pump inhibitor ( PPIs ) H2receptor antagonists control upper GI disease within previous 2 week . Have take NSAIDs ( include aspirin ) within 2 week study enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>